ArticleProstate international2026
Testosterone dynamics and oncologic safety in biochemically recurrent prostate cancer: An analysis of intermittent androgen deprivation therapy schedules.
Article in Prostate international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Continuous androgen deprivation therapy (cADT) remains the standard treatment for advanced prostate cancer; however, it is associated with morbidity and a reduced quality of life. Intermittent ADT (iADT) is a potential strategy to mitigate these effects; however, the optimal scheduling for iADT remains unclear. This study evaluates the testosterone (T) suppression efficacy and the oncologic safety of different iADT schedules in patients with biochemically recurrent (BCR) prostate cancer. Methods: We conducted a retrospective analysis of 119 men with castrate T levels (<20 ng/dL) and stable prostate-specific antigen (PSA) nadirs following cADT for BCR after radical prostatectomy or radiotherapy. Patients underwent iADT using one of three schedules: 1-on/1-off, 1-on/2-off, or 3-on/3-off months. We tracked serum T and PSA kinetics, and incidence rates of T breakthrough during a median follow-up of 12.0 months. Predictors of T breakthrough were investigated. Results: The three groups had no differences in baseline clinicopathological and laboratory features. The 1-on/1-off regimen effectively suppressed serum T for up to six months, while 1-on/2-off and 3-on/3-off schedules were associated with higher incidences of T breakthrough ( Conclusion: A 1-on/1-off iADT schedule may offer a clinically viable alternative to cADT in maintaining successful T suppression. iADT may be particularly useful in patients seeking to reduce ADT side effects. Further studies are needed to validate these findings and optimize iADT protocols.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.